A new generation of hydrocolloid dressings in combination with topical corticosteroids in the treatment of psoriasis vulgaris

Journal of the European Academy of Dermatology and Venereology

Volumn 9, Issue 1, 1997, Pages 50-53

  Dezfoulian B ^a   De La Brassinne, M ^a   Rosillon, D ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Bio Pharma SA   (Belgium)

Author keywords

Betamethasone 17 valerate; Clobetasol propionate; Hydrocolloid dressings; Occlusion; Psoriasis; Topical corticosteroids

Indexed keywords

BETAMETHASONE VALERATE; CLOBETASOL PROPIONATE; CORTICOSTEROID;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; HEALING; HUMAN; HYDROCOLLOID; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0030753692     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0926-9959(97)00625-9     Document Type: Article

References (17)

1. Petersen LJ, Kristensen JK. Time-course of corticosteroid-induced blood flow reduction in normal cutaneous tissue-quantitative measurements during 72 h of treatment. Clin Exp Dermatol 1989;14(3):210-213.
2. Somerma S. The chamber vasoconstrictor assay. 1. Comparison with occluded and unoccluded tests using four corticosteroids. Clin Exp Dermatol 1980;5:191-196.
3. 2-consumption and blood flow measurements compared to clinical parameters. Clin Exp Dermatol 1989;14(2):137-140.
4. Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Derm Venereol 1992;72(1):69-71.
5. Schmoll M, Henseler T, Christophers E. Evaluation of PUVA, topical corticosteroids and the combination of both in the treatment of psoriasis. Br J Dermatol 1978;99(6):693-702.
6. Friedman SJ. Management of psoriasis vulgaris with a hydrocolloid occlusive dressing. Arch Dermatol 1987;123(8): 1046-1052.
7. David M, Lowe NJ. Psoriasis therapy: comparative studies with a hydrocolloid dressing, plastic film occlusion, and triamcinolone acetonide cream. J Am Acad Dermatol 1989;21(3 Pt 1):511-514.
8. Juhlin L. Treatment of psoriasis and other dermatoses with a single application of a corticosteroid left under a hydrocolloid occlusive dressing for one week. Acta Derm Venereol 1989;69(4):355-357.
9. Gonzalez JR, Caban F. Treatment of psoriasis with triamcinolone acetonide 0.1% under occlusion: a comparison of two hydrocolloid dressings. Bol Asoc Med P R 1990;82(7):288-291.
10. Broby-Johansen U, Karlsmark T, Petersen LJ, Serup J. Ranking of the antipsoriatic effect of various topical corticosteroids applied under a hydrocolloid dressing: skin-thickness, blood-flow and colour measurements compared to clinical assessments. Clin Exp Dermatol 1990;15(5):343-348.
11. Fry L, Almeijda J, McMinn RMH. Effect of plastic occlusive dressings on psoriatic epidermis. Br J Dermatol 1970;82: 458-462.
12. Fisher LB, Maibach H, Trancik RF. Effect of occlusive tape systems on the mitotic activity of epidermis: with and without occlusion. Arch. Dermatol 1978;114:384-386.
13. Gottlieb AB, Cohen SR, Carter DM. Efficacy of Actiderm in the treatment of psoriasis. In: Ryan TJ, ed. Beyond Occlusion: Dermatology Proceedings. London: Royal Society of Medicine 1988: 25-34.
14. Proksch E, Feingold KR, Elias PM. Barrier function regulates epidermal DNA synthesis. J Invest Dermatol 1990;94:568.
15. Lotti T, Bonan P, Cannarozzo G, Fedi AM, Panconesi E. Antipsoriatic therapies inhibit epidermal plasminogen activator activity. Int J Dermatol 1990;29(7):528-530.
16. Marriott C, Martin GP. Preclinical results of a new dermatological patch used in conjunction with topical corticosteroids in inducing the blanching response. In: Ryan TJ, ed. Beyond Occlusion: Dermatology Proceedings. London: Royal Society of Medicine 1988:9-24.
17. Queen D, Martin GP, Marriott C, Fairbrother JE. Assessment of the potential of a new hydrocolloid dermatological patch (Actiderm) in the treatment of steroidresponsive dermatoses. Int J Pharm 1988;4:25-30.